

The TIGIT Therapies Digital Summit 26-27 October 2020 ONLINE

October 1, 2020 - The TIGIT checkpoint has gained much attention in recent years due to the number of roles it plays in several malignancies. TIGIT's diverse function in multiple cell types has made it a lucrative immunotherapy candidate, with an increasing number of candidates being investigated in pre-clinical and clinical settings.



As evidence of TIGIT's clinical potential builds, the [TIGIT Therapies Digital Summit](#) brings you a comprehensive insight, from the fundamental biology to early clinical development, and the next wave of ICI.

Leaders in TIGIT development from Merck, Compugen, iTeos Therapeutics, Agenus are working to prime the immune system against solid tumors by leveraging immune checkpoint blockade, which has proven to be an effective tool in multiple malignancies.

Following the success of PD1/PDL1 checkpoint inhibitors a new wave of ICI now enters the clinic, amongst which TIGIT has shown exciting preliminary results and sparked great excitement in this nascent field. With 27 ongoing clinical trials investigating TIGIT in front- and second-line indications, a great deal of momentum has built in this competitive space.

However, core challenges must still be addressed by the community, such as investigating the TIGIT pathway, ligands, and modes of action, optimizing biomarker strategy to identify optimal patient populations and indications, and rationalizing combination strategy to leverage the TIGIT mechanism for maximum therapeutic benefit.

The TIGIT Therapies Digital Summit will gather all the greatest minds in TIGIT research under one virtual roof. Gain access to 1:1 time with leaders in TIGIT research and take away tangible learnings.

In such a fast-paced industry, this is a unique opportunity to provide an overview of the 'knowns and unknowns' in the field, and draw a path for best practice in the safe development of TIGIT therapies with maximum clinical impact.

At a time when we are more isolated than ever, this meeting will break down barriers and provide the opportunity for frank and open discussion to ensure the continued progress and development of TIGIT therapies.

Register: <https://go.evvnt.com/666284-2?pid=4509>

Brochure: <https://go.evvnt.com/666284-3?pid=4509>